O	0	11	Multicenter
O	12	17	phase
O	18	20	II
O	21	31	randomized
O	32	37	trial
O	38	48	evaluating
B-intervention	49	63	antiangiogenic
I-intervention	64	71	therapy
I-intervention	72	76	with
I-intervention	77	86	sunitinib
O	87	89	as
O	90	103	consolidation
O	104	109	after
O	110	119	objective
O	120	128	response
O	129	131	to
O	132	138	taxane
O	139	151	chemotherapy
O	152	154	in
O	155	160	women
O	161	165	with
O	166	170	HER2
O	170	171	-
O	171	179	negative
O	180	190	metastatic
O	191	197	breast
O	198	204	cancer
O	204	205	.

O	206	209	The
O	210	213	aim
O	214	216	of
O	217	221	this
O	222	227	study
O	228	230	is
O	231	233	to
O	234	238	test
O	239	242	the
O	243	253	hypothesis
O	254	258	that
O	259	273	antiangiogenic
O	274	283	treatment
O	284	288	with
O	289	298	sunitinib
O	299	312	consolidation
O	313	316	can
O	317	324	prolong
O	325	335	remissions
O	336	343	induced
O	344	346	by
O	347	353	taxane
O	353	354	-
O	354	359	based
O	360	372	chemotherapy
O	373	375	in
O	376	381	women
O	382	386	with
O	387	397	metastatic
O	398	404	breast
O	405	411	cancer
O	411	412	.

O	413	416	The
O	417	423	method
O	424	432	involves
O	433	434	a
O	435	438	two
O	438	439	-
O	439	442	arm
O	443	447	open
O	447	448	-
O	448	453	label
O	454	455	(
O	455	456	2
O	456	457	:
O	457	458	1
O	459	472	randomization
O	472	473	)
O	474	485	multicenter
O	485	486	,
O	487	497	randomized
O	498	503	phase
O	504	506	II
O	507	512	trial
O	513	523	evaluating
O	524	527	the
O	528	536	efficacy
O	537	539	of
O	540	549	sunitinib
O	550	551	(
O	551	554	arm
O	555	556	A
O	556	557	)
O	558	564	versus
B-control	565	567	no
I-control	568	575	therapy
O	576	577	(
O	577	580	arm
O	581	582	B
O	582	583	)
O	584	586	in
B-eligibility	587	595	patients
I-eligibility	596	600	with
I-eligibility	601	604	HER
I-eligibility	604	605	-
I-eligibility	605	606	2
I-eligibility	606	607	-
I-eligibility	607	615	negative
I-eligibility	616	626	metastatic
I-eligibility	627	633	breast
I-eligibility	634	640	cancer
I-eligibility	641	644	who
I-eligibility	645	653	achieved
I-eligibility	654	656	an
I-eligibility	657	666	objective
I-eligibility	667	675	response
I-eligibility	676	678	to
I-eligibility	679	685	taxane
I-eligibility	685	686	-
I-eligibility	686	691	based
I-eligibility	692	704	chemotherapy
O	704	705	.

O	706	709	The
O	710	717	results
O	718	720	of
O	721	725	this
O	726	731	study
O	732	741	indicates
O	742	746	that
O	747	750	the
O	751	758	primary
O	759	767	endpoint
O	768	770	of
B-outcome	771	782	progression
I-outcome	782	783	-
I-outcome	783	787	free
I-outcome	788	796	survival
I-outcome	797	798	(
I-outcome	798	801	PFS
I-outcome	801	802	)
I-outcome	803	804	>
I-outcome	805	807	or
I-outcome	808	809	=
I-outcome	809	810	5
I-outcome	811	817	months
O	818	821	was
O	822	830	achieved
O	831	833	in
B-iv-bin-abs	834	836	10
O	837	839	of
B-intervention-participants	840	842	36
O	843	851	patients
O	852	853	(
B-iv-bin-percent	853	855	28
I-iv-bin-percent	855	856	%
O	856	857	)
O	858	860	in
O	861	864	arm
O	865	866	A
O	867	870	and
B-cv-bin-abs	871	872	4
O	873	875	of
B-control-participants	876	878	19
O	879	887	patients
O	888	889	(
B-cv-bin-percent	889	891	21
I-cv-bin-percent	891	892	%
O	892	893	)
O	894	896	in
O	897	900	arm
O	901	902	B
O	902	903	.

O	904	907	The
B-outcome	908	914	median
I-outcome	915	918	PFS
O	919	922	was
B-iv-cont-median	923	924	2
I-iv-cont-median	924	925	.
I-iv-cont-median	925	926	8
O	927	930	and
B-cv-cont-median	931	932	3
I-cv-cont-median	932	933	.
I-cv-cont-median	933	934	1
I-cv-cont-median	935	941	months
O	941	942	,
O	943	955	respectively
O	955	956	.

O	957	958	A
O	959	967	protocol
O	968	977	amendment
O	978	980	to
O	981	984	the
O	985	994	sunitinib
O	995	1001	dosing
O	1002	1010	schedule
O	1011	1014	was
O	1015	1019	made
O	1020	1027	because
O	1028	1030	53
O	1030	1031	%
O	1032	1033	(
O	1033	1035	17
O	1035	1036	/
O	1036	1038	32
O	1038	1039	)
O	1040	1042	of
O	1043	1051	patients
O	1052	1059	treated
O	1060	1062	at
O	1063	1064	a
O	1065	1073	starting
O	1074	1078	dose
O	1079	1081	of
O	1082	1084	50
O	1085	1087	mg
O	1088	1089	(
O	1089	1090	4
O	1091	1096	weeks
O	1097	1099	on
O	1099	1100	/
O	1100	1101	2
O	1102	1107	weeks
O	1108	1111	off
O	1111	1112	)
B-outcome	1113	1121	required
I-outcome	1122	1126	dose
I-outcome	1127	1136	reduction
O	1136	1137	.

O	1138	1146	Changing
O	1147	1150	the
O	1151	1159	starting
O	1160	1164	dose
O	1165	1167	to
O	1168	1177	sunitinib
O	1178	1180	37
O	1180	1181	.
O	1181	1182	5
O	1183	1185	mg
O	1186	1198	continuously
O	1199	1207	resulted
O	1208	1210	in
B-outcome	1211	1215	dose
I-outcome	1216	1226	reductions
O	1227	1229	in
O	1230	1232	44
O	1232	1233	%
O	1234	1235	(
O	1235	1236	7
O	1236	1237	/
O	1237	1239	16
O	1239	1240	)
O	1241	1243	of
O	1244	1252	patients
O	1252	1253	.

B-outcome	1254	1260	Grades
I-outcome	1261	1264	III
I-outcome	1264	1265	-
I-outcome	1265	1267	IV
I-outcome	1268	1276	toxicity
O	1277	1285	occurred
O	1286	1288	in
B-iv-bin-percent	1289	1291	69
I-iv-bin-percent	1291	1292	%
O	1293	1295	of
O	1296	1304	patients
O	1305	1307	in
O	1308	1311	arm
O	1312	1313	A
O	1314	1315	(
B-outcome	1315	1322	fatigue
B-iv-bin-percent	1323	1325	31
I-iv-bin-percent	1325	1326	%
O	1326	1327	,
B-outcome	1328	1343	musculoskeletal
I-outcome	1344	1348	pain
B-iv-bin-percent	1349	1351	11
I-iv-bin-percent	1351	1352	%
O	1352	1353	,
B-outcome	1354	1365	neutropenia
I-outcome	1366	1369	and
I-outcome	1370	1382	thrombopenia
I-outcome	1383	1384	8
I-outcome	1384	1385	%
O	1385	1386	)
O	1387	1390	and
B-cv-bin-percent	1391	1393	11
I-cv-bin-percent	1393	1394	%
O	1395	1397	in
O	1398	1401	arm
O	1402	1403	B
O	1403	1404	.

O	1405	1408	The
O	1409	1414	proof
O	1414	1415	-
O	1415	1417	of
O	1417	1418	-
O	1418	1427	principle
O	1428	1433	study
O	1434	1438	does
O	1439	1442	not
O	1443	1450	confirm
O	1451	1454	the
O	1455	1465	hypothesis
O	1466	1470	that
O	1471	1480	sunitinib
O	1481	1494	consolidation
O	1495	1502	therapy
O	1503	1506	can
O	1507	1511	lead
O	1512	1514	to
O	1515	1516	a
O	1517	1527	predefined
O	1528	1538	clinically
O	1539	1547	relevant
O	1548	1558	proportion
O	1559	1561	of
O	1562	1570	patients
O	1571	1575	with
O	1576	1579	PFS
O	1580	1582	of
O	1583	1584	>
O	1585	1587	or
O	1588	1589	=
O	1589	1590	5
O	1591	1597	months
O	1598	1603	after
O	1604	1606	an
O	1607	1616	objective
O	1617	1625	response
O	1626	1628	to
O	1629	1636	taxanes
O	1636	1637	.

O	1638	1649	Furthermore
O	1649	1650	,
O	1651	1659	toxicity
O	1660	1663	was
O	1664	1675	significant
O	1675	1676	.
